bionomics.com.au (BNOX) - Long-Term Debt to Capital Coefficient

Bionomics - graphic logo of issuer BNOX

Bionomics Limited (BNOX) is a biotech startup developing anxiety treatments whose future pricing power relies on exclusive patents. The business is based on flexible international raw material supplies and collaborations with various research centers to minimize risks. The share price history, where the indicator is 0.01, demonstrates a dependence on clinical trial outcomes amid a lack of current sales and high R&D costs.

bionomics.com.au (BNOX): Long-Term Debt to Equity from 07/04/2022 to 12/24/2024

Comprehensive metric breakdowns and analytics for Bionomics Ltd. (BNOX)

- stock price and consensus target price:
Quote Chart Bionomics Ltd|BNOX - Analyst Consensus Forecast
- market capitalization indicators:
Market Value Bionomics Limited|BNOX - Enterprise Value
- balance sheet net asset value indicators:
Book Value per Share Bionomics|BNOX - Company Book Value|Market Value to Book Value bionomics.com.au|BNOX - Aggregate Company Assets
- debt and solvency information:
Total Debt to Equity Ratio Bionomics Limited|BNOX - Long-Term Debt to Capital|Short-Term Debt to Capital Bionomics Ltd|BNOX - Company Total Debt|Debt to Net Assets Ratio Bionomics Limited|BNOX - Company Long-Term Debt|Company Short-Term Indebtedness Bionomics|Immediate Liquidity bionomics.com.au
- net income and valuation ratios data:
BNOX - Net Income
General company analysis:bionomics.com.au - BNOX
Signature product of Bionomics Ltd.

This indicator compares liabilities with maturities exceeding one year against current market capitalization to assess financial stability. For Bionomics Limited (BNOX), such a debt structure is justified by the development of innovative drugs for PTSD and anxiety disorders. Analyzing the ratio of long-term debt to equity reveals the balance between credit risks and expansion. An increase in this metric reflects investments in scaling the business, serving as a key marker of solvency during aggressive growth.

Analysis of competing companies

Jazz Pharmaceuticals PLC - Long-Term Liabilities to Equity|Long-Term Debt to Capital CYTK|PTCT (PTC Bio) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Capital SRRK (Scholar Rock)|Long-Term Debt to Capital centessa.com CNTA|DYN - Long-Term Debt to Equity|Long-Term Debt to Capital Coefficient EWTX (Edgewise Therapeutics Inc)|Rapport Pharma (RAPP) - Long-Term Debt to Equity|Long-Term Debt to Equity Ratio Alumis Pharma|ZVRA (Zevra Therapeutics) - Long-Term Debt to Capital|Long-Term Debt to Capital contineum-tx.com|Long-Term Debt to Equity Ratio LRMR (Larimar Therapeutics, Inc.)|CAPR (capricor.com) - Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity Entrada TRDA|PTHS: Long-Term Debt to Capital Ratio|MediciNova Corp - Long-Term Debt to Capital|Long-Term Liabilities to Capital serinatherapeutics.com|BTAI (BioXcel Therapeutics, Inc.) - Long-Term Debt to Equity Ratio|ProMIS Neurosciences, Inc. (PMN) - Long-Term Debt to Capital|Long-Term Debt to Equity Apimeds Pharmaceuticals, Inc.|AEON: Long-Term Debt to Capital Coefficient|Long-Term Debt to Equity NLS Pharmaceutics AG (NLSP)|HUGE - Long-Term Liabilities to Capital|Long-Term Debt to Equity Reata Pharmaceuticals, Inc. RETA